Company News

Share this article:

Sanofi-Aventis will acquire California-based BiPar Sciences for up to $500 million. BiPar Sciences is a pharma focused on a novel cancer treatment, known as BSI-201. The acquisition is the third this month for Sanofi – the company purchased Medley, a Brazillian generics manufacturer, and Laboratorious Kendrick, a Mexican generic company.

 

Johnson & Johnson announced that it will shift its wellness and disease-prevention business under the consumer business umbrella. J&J had initially planned to develop a separate wellness and disease-prevention business, with the acquisition of Michigan-based HealthMedia, according to a Wall Street Journal report.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.